Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 11/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2259697 | 1.00 | P2RX3 (0.32) | P2RX3P2RX2NPC1LMNAMAPT | |
| SCHEMBL21452315 | 0.80 | P2RX3 (0.33) | P2RX3P2RX2NPC1LMNAMAPT | |
| SCHEMBL17845775 | 0.79 | — | — | |
| SCHEMBL17445187 | 0.78 | P2RX3 (0.33) | P2RX3P2RX2NPC1LMNAMAPT | |
| SCHEMBL21452313 | 0.76 | SMN1; SMN2 (0.38) | P2RX3P2RX2LMNASMN1; SMN2 | |
| SCHEMBL10115678 | 0.74 | ESR1 (0.32) | — | |
| SCHEMBL13841338 | 0.74 | ESR1 (0.32) | — | |
| SCHEMBL13104802 | 0.74 | ESR1 (0.32) | — | |
| SCHEMBL10075871 | 0.74 | ESR1 (0.32) | — | |
| SCHEMBL469175 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | P2RX3 1/4885P2RX2 3/4885NPC1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.